211At-MABG for Neuroendocrine Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).
Who Is on the Research Team?
Vivek Narayan, MD, MS
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for adults with advanced neuroendocrine cancers, such as pheochromocytoma, paraganglioma, or medullary thyroid cancer. Participants must have tumors that show up on MIBG scans and either not respond to, lack access to, or can't receive standard treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 211At-MABG
Trial Overview
Researchers are testing different doses of a new radioactive drug called 211At-MABG given in fractions to see what dose is safest and best tolerated in people with these cancers. The study uses a step-by-step approach where small groups get increasing doses.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
One treatment cycle (4 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (1 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).
One treatment cycle (2 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.5 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).
One treatment cycle (1 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.25 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.